What is the Market Cap of Lupin?

It indicates the value of the outstanding shares of a publicly traded firm. As of {{todaydate}}, Lupin's market cap stands at Rs {{price}} crores.

Is Lupin part of Nifty 50?

Yes, Lupin belongs to the Nifty 50 index.

What is the dividend of Lupin in 2023?

In March 2023, Lupin declared an equity dividend of 200% with Rs 4 per share. The company's current share price provided a 0.25% dividend yield.

Is Lupin a debt-free company?

Lupin can be virtually considered debt-free, with a PEG ratio of 0.22 and a smooth conversion cycle of 65.84 days.

Is Lupin a good stock to buy?

Lupin seems like a good stock to buy on the basis of its current market price, future growth prospects, and profit margins. Moreover, the company has no threat of bankruptcy in the near future.

What is the future of Lupin Limited's shares?

Lupin Limited's shares are going to increase in value in the future as the company is focusing on enhanced patient care and drug development to generate fresh revenue streams.

What is Lupin Ltd Share symbol?

Lupin Ltd. has a share symbol of LUPIN.

Who is/are the promoter/promoters of Lupin Ltd?

The promoters of Lupin Ltd. include Punita Kumar Sinha, K B S Anand, Mark D McDade, Ramesh Swaminathan, Jean-Luc Belingard, R V Satam, Vinita Gupta, Nilesh Deshbandhu Gupta, and M D Gupta.

Who are peers of Lupin Ltd?

The peers of Lupin Ltd. include Divi's Laboratories Ltd., Gland Pharma Ltd., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Zydus Lifesciences Ltd., and Alkem Laboratories Ltd.

Who's the owner of Lupin?

Promoters, DII, and DII hold 47.06, 29.0, and 14.99 shares of Lupin. During the period between 30 Sep 2023 and 31 Dec 2023, the holdings have changed in the following ways: Promoter holding reduced from 47.06 to 47.04. DII holding increased from 29.0 to 29.58. FII holding increased from 14.99 to 16.11. Other investor holdings reduced from 8.95 to 7.27.

What is the 52 Week High and Low of Lupin?

The highest and lowest prices of Lupin over a period of 52 weeks are important trading indicators. Lupin showed a 52-week high of Rs 1700 and a 52-week low of Rs 628 as of 14 Feb 2024.

What is the PE and PB ratio of Lupin?

Lupin has a PE ratio of 40.9 and a PB ratio of 5.53.

What is the Share Price of Lupin?

Owing to the volatility in the arena of stocks, the share price of Lupin keeps fluctuating. As of 14 Feb 2024, Lupin's share price stands at Rs 0.00.

How to Buy Lupin Share?

If you want to purchase Lupin shares, create a demat account with IIFL. Submit proper KYC paperwork and undergo verification while making your account.

Lupin Share Price

Sector: Pharmaceuticals | ISIN: INE326A01037

₹ 1,632.80 (1.04%)

2 Jul, 2024, 12:00:00 AM

Trade

Expiry Date:

LUPIN - 25-07-2024

CALLS						PUTS
Total OI	Chg in Ol	Chg % Ol	LTP	Chg %	Strike Price	Chg %	LTP	Chg % OI	Chg in Ol	Total OI
425	0	0.00	317.75	0.00	1,300.00	-11.11	0.8	0.0	0	4675
14450	0	0.00	264.95	0.00	1,360.00	-44.00	0.7	0.0	0	13600
11475	0	0.00	206.85	0.00	1,400.00	-17.07	1.7	-22.88	-11475	38675
850	0	0.00	151	0.00	1,420.00	-38.46	2	-4.55	-425	8925
-	-	-	-	0.00	1,440.00	-7.81	2.95	-13.33	-5950	38675
425	0	0.00	167.55	0.00	1,460.00	-24.69	3.05	21.95	3825	21250
1700	425	33.33	147.75	33.33	1,480.00	-26.17	3.95	6.77	3825	60350
17850	0	0.00	140	0.00	1,500.00	-28.19	5.35	8.51	17425	222275
6375	0	0.00	103.8	0.00	1,520.00	-30.35	7	9.9	4250	47175
10625	0	0.00	102.95	0.00	1,540.00	-30.51	9.45	19.51	10200	62475

Lupin Ltd Corporate Actions

22 Apr , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

22 Apr , 2024

12:00 AM

Results

View Details

22 Mar , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

24 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

24 Jan , 2024

12:00 AM

Results

View Details

25 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

25 Oct , 2023

12:00 AM

Results

View Details

04 Jul , 2023

12:00 AM

AGM

Announcement date: 04 Jul , 2023

View Details

21 Jul , 2023

12:00 AM

Results

View Details

21 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

09 May , 2023

12:00 AM

Dividend

Dividend amount: 4
Announcement date: 09 May , 2023

View Details

No Record Found

Lupin Ltd News and Update

European Court of Justice upholds 40 million Euro fine on Lupin

According to reports, the sanctions were imposed as a result of their participation in "pay-for-delay" arrangements from 2005 to 2007.

Lupin's European arm acquires Aarane and Nalcrom brands from Sanofi

This strategic move aligns with Lupin's goal of expanding its global presence in specialty areas.

06 Jun, 2024 |
9:20 AM

Lupin’s Somerset facility receives 6 observations in pre-approval USFDA inspection

Lupin said the business is thoroughly reviewing the findings and would respond to the USFDA within the timeframe specified.

21 May, 2024 |
11:41 AM

Lupin’s Q4 net profit up by 52% to ₹359 Crore

Profit before tax was lower in Q4 FY2024 due to an impairment charge of ₹201.3 Crore. The quarter's R&D investment totaled ₹425.5 Crore (8.7% of revenue).

07 May, 2024 |
10:39 AM

Lupin Ltd FINANCIALS

Y/e 31 Mar( In .Cr)	Mar-2022	Mar-2021	Mar-2020	Mar-2018
Revenue	16405.48	15162.96	15374.76	15796.55
yoy growth (%)	8.19	(1.38)	(2.67)	(9.04)
Raw materials	(6,481.24)	(5,362.24)	(5,430.60)	(5,274.40)
As % of sales	39.51	35.36	35.32	33.39
Employee costs	(2,989.30)	(2,825.90)	(2,986.84)	(2,864.71)
As % of sales	18.22	18.64	19.43	18.14
Other costs	(6,716.12)	(4,407.94)	(4,602.52)	(4,509.93)
As % of sales	40.94	29.07	29.94	28.55
Operating profit	218.82	2566.88	2354.80	3147.51
OPM	1.33	16.93	15.32	19.93
Depreciation	(1,658.71)	(887.41)	(970.22)	(1,085.87)
Interest expense	(142.77)	(140.64)	(362.98)	(204.35)
Other income	210.09	136.29	483.76	153.87
Profit before tax	(1,372.57)	1675.12	1505.36	2011.16
Taxes	(137.15)	(448.52)	(1,157.11)	(288.46)
Tax rate	9.99	(26.77)	(76.87)	(14.34)
Minorities and other	(18.68)	(11.40)	130.49	(7.09)
Adj. profit	(1,528.40)	1215.20	478.74	1715.61
Exceptional items	--	--	(752.07)	(1,464.35)
Net profit	(1,528.04)	1216.53	(269.39)	251.26
yoy growth (%)	(225.61)	(551.59)	(207.22)	(90.17)
NPM	(9.31)	8.02	(1.75)	1.59

Y/e 31 Mar ( In .Cr)	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Equity capital	91	90.90	90.79	90.68
Preference capital	--	--	--	--
Reserves	12373.50	12062.37	13712.35	12446.02
Net worth	12464.50	12153.27	13803.14	12536.70
Minority interest	78.32	68.71	54.97	44.46
Debt	4541.52	4158.38	5129.08	6305.32
Deferred tax liabilities (net)	229.43	240.83	229.77	199.54
Total liabilities	17313.77	16621.19	19216.96	19086.02
Fixed assets	9593.23	8527.90	8947.02	8877.73
Intangible assets	--	--	--	--
Investments	516.90	900	2454.88	2374.32
Deferred tax asset (net)	155.65	169.73	180.21	174.31
Net working capital	5754.86	5925.43	5892.39	5205.36
Inventories	4491.76	4630.73	4092.01	3456.87
Inventory Days	--	103.03	98.50	82.07
Sundry debtors	4480.70	4261.94	4474.32	5445.93
Debtor days	--	94.82	107.70	129.29
Other current assets	2424.56	2232.79	1719.54	2200.39
Sundry creditors	(2,597.95)	(2,366.70)	(2,126.42)	(2,388.25)
Creditor days	--	52.66	51.19	56.70
Other current liabilities	(3,044.21)	(2,833.33)	(2,267.06)	(3,509.58)
Cash	1293.13	1098.13	1742.46	2454.30
Total assets	17313.77	16621.19	19216.96	19086.02

Y/e 31 Mar ( In .Cr)	Mar-2022	Mar-2021	Mar-2020	Mar-2018
Profit before tax	(1,372.57)	1675.12	1505.36	2011.16
Depreciation	(1,658.71)	(887.41)	(970.22)	(1,085.87)
Tax paid	(137.15)	(448.52)	(1,157.11)	(288.46)
Working capital 27,893	5293.32	5599.58	5308.16	3800.16
Other operating items	--	--	--	--
Operating cashflow	2124.89	5938.77	4686.19	4436.99
Capital expenditure	13025.96	10534.91	9476.29	8575.96
Free cash flow	15150.85	16473.68	14162.48	13012.95
Equity raised	16783.91	16420.84	17831.25	20304.05
Investments	896.85	2452.08	2372.26	83.10
Debt financing/disposal	3879.81	5241.06	6231.31	7581.34
Dividends paid	--	--	--	226.04
Net in cash	36711.42	40587.66	40597.30	41207.48

Y/e 31 Mar	Mar-2022	Mar-2021	Mar-2020	Mar-2018
Growth matrix (%)
Revenue growth	8.194	-1.378	-2.67	-9.045
Op profit growth	-91.475	9.006	-25.185	-29.949
EBIT growth	-167.729	-2.814	-15.67	-39.917
Net profit growth	-225.606	-551.587	-207.216	-90.175
Profitability ratios (%)
OPM	1.334	16.929	15.316	19.925
EBIT margin	-7.496	11.975	12.152	14.025
Net profit margin	-9.314	8.023	-1.752	1.591
RoCE	-6.863	9.481	9.311	10.319
RoNW	-2.943	2.309	-0.516	0.464
RoA	-2.132	1.588	-0.336	0.293
Per share ratios (₹)
EPS	-33.21	27.06	-5.96	5.71
Dividend per share	4	6.5	6	5
Cash EPS	-70.119	7.254	-27.365	-18.461
Book value per share	-6.863	9.481	9.311	10.319
Valuation ratios
P/E	-22.465	37.729	-98.943	128.967
P/CEPS	-10.64	140.734	-21.55	-39.889
P/B	2.79	3.356	2.131	2.452
EV/EBIDTA	86.187	18.388	10.768	11.821
Payout (%)
Dividend payout	0	0	0	89.963
Tax payout	9.992	-26.775	-76.866	-14.343
Liquidity ratios
Debtor days	97.185	119.399	126.276	109.75
Inventory days	97.035	90.858	84.508	84.393
Creditor days	-50.659	-65.411	-68.924	-71.772
Leverage ratios
Interest coverage	8.614	-12.911	-5.147	-10.842
Net debt / equity	0.252	0.245	0.307	0.422
Net debt / op. profit	13.985	1.319	1.635	1.822
Cost breakup (₹)
Material costs	-39.507	-35.364	-35.322	-33.39
Employee costs	-18.221	-18.637	-19.427	-18.135
Other costs	-40.938	-29.07	-29.936	-28.55

Select Period:

Particulars ( Rupees In Crores.)	--	--	--	--
Gross Sales	--	--	--	--
Excise Duty	--	--	--	--
Net Sales	--	--	--	--
Other Operating Income	--	--	--	--
Other Income	--	--	--	--
Total Income	--	--	--	--
Total Expenditure **	--	--	--	--
PBIDT	--	--	--	--
Interest	--	--	--	--
PBDT	--	--	--	--
Depreciation	--	--	--	--
Minority Interest Before NP	--	--	--	--
Tax	--	--	--	--
Deferred Tax	--	--	--	--
Reported Profit After Tax	--	--	--	--
Minority Interest After NP	--	--	--	--
Net Profit after Minority Interest	--	--	--	--
Extra-ordinary Items	--	--	--	--
Adjusted Profit After Extra-ordinary item	--	--	--	--
EPS (Unit Curr.)	--	--	--	--
Book Value (Unit Curr.)	--	--	--	--
Dividend (%)	--	--	--	--
Equity	--	--	--	--
Public Shareholding (Number)	--	--	--	--
Public Shareholding (%)	--	--	--	--
Pledged/Encumbered - No. of Shares	--	--	--	--
Pledged/Encumbered - % in Total Promoters Holding	--	--	--	--
Pledged/Encumbered - % in Total Equity	--	--	--	--
Non Encumbered - No. of Shares	--	--	--	--
Non Encumbered - % in Total Promoters Holding	--	--	--	--
Non Encumbered - % in Total Equity	--	--	--	--
PBIDTM(%)	--	--	--	--
PBDTM(%)	--	--	--	--
PATM(%)	--	--	--	--

No Record Found

Particulars ( Rupees In Crores.)	--	--	--	--
Gross Sales	--	--	--	--
Excise Duty	--	--	--	--
Net Sales	--	--	--	--
Other Operating Income	--	--	--	--
Other Income	--	--	--	--
Total Income	--	--	--	--
Total Expenditure **	--	--	--	--
PBIDT	--	--	--	--
Interest	--	--	--	--
PBDT	--	--	--	--
Depreciation	--	--	--	--
Minority Interest Before NP	--	--	--	--
Tax	--	--	--	--
Deferred Tax	--	--	--	--
Reported Profit After Tax	--	--	--	--
Minority Interest After NP	--	--	--	--
Net Profit after Minority Interest	--	--	--	--
Extra-ordinary Items	--	--	--	--
Adjusted Profit After Extra-ordinary item	--	--	--	--
EPS (Unit Curr.)	--	--	--	--
Book Value (Unit Curr.)	--	--	--	--
Dividend (%)	--	--	--	--
Equity	--	--	--	--
Public Shareholding (Number)	--	--	--	--
Public Shareholding (%)	--	--	--	--
Pledged/Encumbered - No. of Shares	--	--	--	--
Pledged/Encumbered - % in Total Promoters Holding	--	--	--	--
Pledged/Encumbered - % in Total Equity	--	--	--	--
Non Encumbered - No. of Shares	--	--	--	--
Non Encumbered - % in Total Promoters Holding	--	--	--	--
Non Encumbered - % in Total Equity	--	--	--	--
PBIDTM(%)	--	--	--	--
PBDTM(%)	--	--	--	--
PATM(%)	--	--	--	--

No Record Found

Lupin Ltd PEER COMPARISON

Company Name	LTP (₹)	P/E (%)	Mkt.Cap (₹Cr.)	NP Qtr (₹Cr.)	Div.Yield (%)	Sales Qtr (₹.Cr)	Book Value (₹)
Sun Pharmaceuticals Industries Ltd	1,524.10	120.29	3,65,682.64	867.60	0.89	5,536.99	98.75
Divis Laboratories Ltd	4,569.75	76.97	1,21,312.50	531.00	0.66	2,259.00	507.94
Cipla Ltd	1,488.45	32.36	1,20,195.02	1,038.40	0.57	3,444.92	346.42
Zydus Lifesciences Ltd	1,074.45	31.35	1,08,114.81	1,405.20	0.28	3,172.60	156.19
Dr Reddys Laboratories Ltd	6,371.65	24.48	1,06,298.05	1,034.80	0.63	5,081.80	1,453.03

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Lupin Ltd

M D Gupta
Chairman (Non-Executive)

Nilesh Deshbandhu Gupta.
Managing Director

Vinita Gupta
Director & Chief Executive Off

R V Satam
Company Sec. & Compli. Officer

Jean-Luc Belingard
Independent Director

Ramesh Swaminathan
Executive Director & CFO

Mark D McDade
Independent Director

K B S Anand
Independent Director

Punita Kumar Sinha
Independent Director

Summary

Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments.Lupin Ltd was incorporated in the year 1983 with the name Lupin Chemicals Ltd. In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar. In the year 1989, the company established a joint venture in Thailand, namely Lupin Chemicals (Thailand) Ltd. In the year 1991, they initiated production of Injectable cephalosporin (bulk and dosages) at Mandideep. In the year 1992, the company set up Fermentation Plant at Tarapur, Maharashtra. Also, Sterile Plant for injectable Cephalosporins (bulk) was commissioned at Mandideep.In the year 2001, Lupin Laboratories Ltd was amalgamated with the company and the name was changed to Lupin Ltd. They commenced supply of Cephalosporin bulk actives to their alliance partners in the US. Also, they commissioned a state of the art US FDA approvable oral cephalosporin bulk active plant. In the year 2002, the company commissioned the new Anti-TB facility at Aurangabad. In the year 2003,... Read More

Reports by Lupin Ltd
Annual ReportAuditors Report
Management DiscussionDirectors Report

Reports by Lupin Ltd
Investor PresentationConference Call TranscriptConference Call Audio

Company FAQ

What is the Market Cap of Lupin?
It indicates the value of the outstanding shares of a publicly traded firm. As of 3 Jul, 2024, Lupin's market cap stands at Rs 74441.96 crores.
Is Lupin part of Nifty 50?
Yes, Lupin belongs to the Nifty 50 index.
What is the dividend of Lupin in 2023?
In March 2023, Lupin declared an equity dividend of 200% with Rs 4 per share. The company's current share price provided a 0.25% dividend yield.
Is Lupin a debt-free company?
Lupin can be virtually considered debt-free, with a PEG ratio of 0.22 and a smooth conversion cycle of 65.84 days.
Is Lupin a good stock to buy?
Lupin seems like a good stock to buy on the basis of its current market price, future growth prospects, and profit margins. Moreover, the company has no threat of bankruptcy in the near future.
What is the future of Lupin Limited's shares?
Lupin Limited's shares are going to increase in value in the future as the company is focusing on enhanced patient care and drug development to generate fresh revenue streams.
What is Lupin Ltd Share symbol?
Lupin Ltd. has a share symbol of LUPIN.
Who is/are the promoter/promoters of Lupin Ltd?
The promoters of Lupin Ltd. include Punita Kumar Sinha, K B S Anand, Mark D McDade, Ramesh Swaminathan, Jean-Luc Belingard, R V Satam, Vinita Gupta, Nilesh Deshbandhu Gupta, and M D Gupta.
Who are peers of Lupin Ltd?
The peers of Lupin Ltd. include Divi's Laboratories Ltd., Gland Pharma Ltd., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Zydus Lifesciences Ltd., and Alkem Laboratories Ltd.
Who's the owner of Lupin?
Promoters, DII, and DII hold 47.06, 29.0, and 14.99 shares of Lupin. During the period between 30 Sep 2023 and 31 Dec 2023, the holdings have changed in the following ways: Promoter holding reduced from 47.06 to 47.04. DII holding increased from 29.0 to 29.58. FII holding increased from 14.99 to 16.11. Other investor holdings reduced from 8.95 to 7.27.
What is the 52 Week High and Low of Lupin?
The highest and lowest prices of Lupin over a period of 52 weeks are important trading indicators. Lupin showed a 52-week high of Rs 1700 and a 52-week low of Rs 628 as of 14 Feb 2024.
What is the PE and PB ratio of Lupin?
Lupin has a PE ratio of 40.9 and a PB ratio of 5.53.
What is the Share Price of Lupin?
Owing to the volatility in the arena of stocks, the share price of Lupin keeps fluctuating. As of 14 Feb 2024, Lupin's share price stands at Rs 0.00.
How to Buy Lupin Share?
If you want to purchase Lupin shares, create a demat account with IIFL. Submit proper KYC paperwork and undergo verification while making your account.

ATTENTION INVESTORS

Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

Risk Disclosure on Derivatives

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to Rs. 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This certificate demonstrates that IIFL as an organization has defined and put in place best-practice information security processes.